Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
285.94 USD   -1.43%
05:19aEisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan
MT
01/30Global markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
01/30UBS Adjusts Biogen's Price Target to $337 From $338, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Growing China COVID-19 Protests Weigh on Equities Amid Growth Worries

11/28/2022 | 12:43pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADOBE INC. -1.97% 363.42 Delayed Quote.10.16%
BIOGEN INC. -1.43% 285.94 Delayed Quote.4.75%
DOW JONES INDUSTRIAL -0.77% 33717.09 Real-time Quote.2.51%
NASDAQ COMPOSITE -1.96% 11393.81 Real-time Quote.8.86%
SHANGHAI A INDEX -0.42% 3412.53 Real-time Quote.5.83%
SHANGHAI STOCK EXCHANGE B SHARES INDEX 0.17% 299.5527 Real-time Quote.6.05%
All news about BIOGEN INC.
05:19aEisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan
MT
01/30Global markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
01/30UBS Adjusts Biogen's Price Target to $337 From $338, Maintains Buy Rating
MT
01/30Sector Update: Health Care Stocks in Red Pre-Bell Monday
MT
01/30It's all about central banks this week
MS
01/30Eisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
01/30Biogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan
MT
01/29Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
RE
01/29Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen
RE
01/29Lecanemab receives priority review status in japan
PR
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 068 M - -
Net income 2022 2 872 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,1x
Yield 2022 -
Capitalization 41 176 M 41 176 M -
EV / Sales 2022 4,12x
EV / Sales 2023 4,05x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 285,94 $
Average target price 322,41 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors